DE60128009D1 - Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma - Google Patents

Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma

Info

Publication number
DE60128009D1
DE60128009D1 DE60128009T DE60128009T DE60128009D1 DE 60128009 D1 DE60128009 D1 DE 60128009D1 DE 60128009 T DE60128009 T DE 60128009T DE 60128009 T DE60128009 T DE 60128009T DE 60128009 D1 DE60128009 D1 DE 60128009D1
Authority
DE
Germany
Prior art keywords
sarp
scleroderma
prevention
treatment
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60128009T
Other languages
English (en)
Other versions
DE60128009T2 (de
Inventor
Christine Plater-Zyberk
Christine Power
Jacques Colinge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems ARS Holding NV filed Critical Applied Research Systems ARS Holding NV
Publication of DE60128009D1 publication Critical patent/DE60128009D1/de
Application granted granted Critical
Publication of DE60128009T2 publication Critical patent/DE60128009T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
DE60128009T 2000-12-06 2001-11-30 Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma Expired - Lifetime DE60128009T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00126771 2000-12-06
EP00126771 2000-12-06
EP01118888 2001-08-17
EP01118888 2001-08-17
PCT/EP2001/013992 WO2002046225A2 (en) 2000-12-06 2001-11-30 Use of sarp-1 for the treatment and/or prevention of scleroderma

Publications (2)

Publication Number Publication Date
DE60128009D1 true DE60128009D1 (de) 2007-05-31
DE60128009T2 DE60128009T2 (de) 2007-08-23

Family

ID=26071647

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60128009T Expired - Lifetime DE60128009T2 (de) 2000-12-06 2001-11-30 Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma

Country Status (30)

Country Link
US (2) US7341995B2 (de)
EP (2) EP1411970B1 (de)
JP (1) JP2004525869A (de)
KR (1) KR100804885B1 (de)
CN (1) CN1323716C (de)
AT (1) ATE359808T1 (de)
AU (2) AU2002226366B2 (de)
BG (1) BG107941A (de)
BR (1) BR0115983A (de)
CA (1) CA2428092A1 (de)
CY (1) CY1107687T1 (de)
CZ (1) CZ20031855A3 (de)
DE (1) DE60128009T2 (de)
DK (1) DK1411970T3 (de)
EA (1) EA005973B1 (de)
EE (1) EE200300213A (de)
ES (1) ES2281463T3 (de)
HK (1) HK1068106A1 (de)
HR (1) HRP20030426A2 (de)
HU (1) HUP0302738A3 (de)
IL (1) IL156069A0 (de)
MX (1) MXPA03005027A (de)
NO (1) NO20032597L (de)
NZ (1) NZ525774A (de)
PL (1) PL365316A1 (de)
PT (1) PT1411970E (de)
SK (1) SK8472003A3 (de)
UA (1) UA83790C2 (de)
WO (1) WO2002046225A2 (de)
YU (1) YU45103A (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4899397A (en) * 1997-02-06 1998-08-26 Genetics Institute, Llc Human sdf-5 protein and compositions
CN1658895A (zh) 2002-04-10 2005-08-24 应用研究***Ars股份公司 护骨素在治疗和／或预防纤维变性疾病中的应用
US7585840B2 (en) 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
US9046537B2 (en) * 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
SE0400489D0 (sv) * 2004-02-27 2004-02-27 Biovitrum Ab Therapeutic proteins
ES2711213T3 (es) * 2005-02-08 2019-04-30 Genzyme Corp Anticuerpos de TGFbeta
JP5025646B2 (ja) * 2005-11-08 2012-09-12 公益財団法人先端医療振興財団 虚血性心疾患の治療方法
US20100260785A1 (en) * 2007-12-13 2010-10-14 Gabriela Saborio SARP-1 Fusion Proteins and Uses Thereof
CA2829592A1 (en) * 2011-03-11 2012-09-20 Celgene Corporation Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
JP4299886B2 (ja) * 1996-09-24 2009-07-22 タノックス インコーポレイテッド アポトーシス関連ペプチドをコードする遺伝子ファミリー、それによってコードされるペプチド、およびそれらの使用方法
US5858715A (en) * 1997-01-29 1999-01-12 Incyte Pharmaceuticals, Inc. Human apoptosis-associated protein
AU4899397A (en) 1997-02-06 1998-08-26 Genetics Institute, Llc Human sdf-5 protein and compositions
PL200586B1 (pl) * 1998-10-16 2009-01-30 Biogen Idec Inc Polipeptydy zawierające mutanty interferonu-beta-1a, kodujące je cząsteczki kwasów nukleinowych, komórki gospodarza transformowane tymi cząsteczkami, sposób wytwarzania polipeptydów, zawierające je kompozycje farmaceutyczne i zastosowania polipeptydów

Also Published As

Publication number Publication date
US20050113291A1 (en) 2005-05-26
US7655628B2 (en) 2010-02-02
EP1411970A2 (de) 2004-04-28
UA83790C2 (ru) 2008-08-26
EP1806144A2 (de) 2007-07-11
CY1107687T1 (el) 2012-05-23
NO20032597D0 (no) 2003-06-06
PL365316A1 (en) 2004-12-27
ES2281463T3 (es) 2007-10-01
IL156069A0 (en) 2003-12-23
HK1068106A1 (en) 2005-04-22
KR20030076585A (ko) 2003-09-26
BR0115983A (pt) 2003-12-30
US7341995B2 (en) 2008-03-11
AU2636602A (en) 2002-06-18
CN1553806A (zh) 2004-12-08
WO2002046225A3 (en) 2004-01-08
YU45103A (sh) 2006-08-17
JP2004525869A (ja) 2004-08-26
DE60128009T2 (de) 2007-08-23
NZ525774A (en) 2006-03-31
EP1806144A3 (de) 2008-04-23
PT1411970E (pt) 2007-05-31
NO20032597L (no) 2003-06-06
WO2002046225A2 (en) 2002-06-13
EA200300639A1 (ru) 2003-12-25
EA005973B1 (ru) 2005-08-25
HRP20030426A2 (en) 2005-04-30
HUP0302738A2 (hu) 2003-11-28
EP1411970B1 (de) 2007-04-18
AU2002226366B2 (en) 2007-03-22
HUP0302738A3 (en) 2010-01-28
CA2428092A1 (en) 2002-06-13
SK8472003A3 (en) 2003-10-07
CN1323716C (zh) 2007-07-04
EE200300213A (et) 2003-08-15
US20080107627A1 (en) 2008-05-08
ATE359808T1 (de) 2007-05-15
KR100804885B1 (ko) 2008-02-20
DK1411970T3 (da) 2007-06-04
CZ20031855A3 (cs) 2003-09-17
BG107941A (bg) 2004-01-30
MXPA03005027A (es) 2003-09-05

Similar Documents

Publication Publication Date Title
DE60142590D1 (de) Verwendung von Botulinum Toxin zur Behandlung von post-operative Schmerzen
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DE60127277D1 (de) Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert
DE60109589D1 (de) Pharmazeutische zusammensetzung zur behandlung von akutem schmerz, chronischem schmerz und/oder neuropathischem schmerz und migräne
DE50214540D1 (de) Stanz bei der behandlung von wunden
ATE342728T1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DE60204966D1 (de) Verwendung von cyclopamine zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE60132851D1 (de) Arzneimittel zur Vorbeugung, Erleichterung oder Behandlung von Hypertension
HK1068106A1 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
DE69638281D1 (de) Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
ATE312104T1 (de) Verbindungen zur behandlung von beeinträchtigten fundischen entspannung
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
HUP0401913A2 (hu) Bromhidrosis kezelésére és megelőzésére szolgáló gyógyszerkészítmény
ATE347888T1 (de) Verwendung von aivlosin zur behandlung und prevention der lawsonia-infektionen in schweinen.
BR0111785A (pt) Composições e métodos para tratamento de candidìase
DE69906701D1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
DE69904297D1 (de) Neue verwendung von ropivacain zur schmerzbehandlung
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DE69924385D1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
DE602004012759D1 (de) Behandlung von fibrosen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: LABORATOIRES SERONO S.A., COINSINS, VAUD, CH